Skip to main content
MRVI logo

MRVI · Maravai Lifesciences Holdings, Inc. · Webcasts, Transcripts & Audio

Track MRVI — free
$7.51 +0.13 (+1.76%) Play latest call Q3 2026 earnings call transcript
Market Cap
$1.92B
Shares
259.94M
Volume · Nov 19 27.57K Avg daily vol (3M) 3.19M

Maravai Lifesciences Holdings, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Maravai Lifesciences Holdings, Inc. (MRVI), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Conference
Investor event
2026-11-17
Maravai Lifesciences Holdings, Inc. (MRVI) November 17, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-12
Maravai Lifesciences Holdings, Inc. (MRVI) November 12, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-11-04
Maravai Lifesciences Holdings, Inc. (MRVI) Q3 2026 Earnings Call Transcript
Confident tone Profitability and financial guidance mRNA revenue growth Clinical pipeline progress and development risk
Revenue
$45.85M
▲ 10.1% YoY
Diluted EPS
$-0.09
Gross margin
35.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2026-08-06
Maravai Lifesciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call Transcript
Confident tone TriLink mRNA Growth ModTail Adoption Commercial Execution
Revenue
$51.44M
▲ 8.5% YoY
Diluted EPS
$-0.08
Gross margin
40.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-04
Maravai Lifesciences Holdings, Inc. (MRVI) June 4, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Maravai Lifesciences Holdings, Inc. (MRVI) Q1 2026 Earnings Call Transcript
Confident tone TriLink revenue growth Cygnus performance Restructuring and cost savings
Revenue
$65.84M
▲ 40.5% YoY
Diluted EPS
$-0.02
Gross margin
51.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Maravai Lifesciences Holdings, Inc. (MRVI) Q4 2025 Earnings Call Transcript
Confident tone Trilink commercial execution and CleanCap 2026 guidance and outlook Adjusted EBITDA recovery
Revenue
$49.87M*
▼ 11.8% YoY
Gross margin
25.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Maravai Lifesciences Holdings, Inc. (MRVI) Q3 2025 Earnings Call Transcript
Positive tone Nucleic Acid Products / TriLink Recovery Product Innovation and Launches Cost Restructuring and EBITDA Improvement
Revenue
$41.63M
▼ 39.7% YoY
Diluted EPS
$-0.18
Gross margin
13.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
Maravai Lifesciences Holdings, Inc. (MRVI) Q2 2025 Earnings Call Transcript
Positive tone Nucleic Acid Production (NAP) / mRNA headwinds Path back to profitability CDMO business
Revenue
$47.40M
▼ 31.7% YoY
Diluted EPS
$-0.27
Gross margin
16.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Maravai Lifesciences Holdings, Inc. (MRVI) Q1 2025 Earnings Call Transcript
Positive tone China / BST export exposure Tariffs and supply chain mitigation Guide RNA / oligo and Molecular Assemblies integration
Revenue
$46.85M
▼ 27% YoY
Diluted EPS
$-0.21
Gross margin
16.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-25
Maravai Lifesciences Holdings, Inc. (MRVI) Q4 2024 Earnings Call Transcript
Cautious tone High-volume CleanCap demand and customer inventory New product launches (CleanScribe, etc.) Flanders 2 facility and commercial pipeline
Revenue
$56.56M*
▼ 23.7% YoY
Gross margin
34.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Maravai Lifesciences Holdings, Inc. (MRVI) Q3 2024 Earnings Call Transcript
Cautious tone Nucleic Acid Production (NAP) segment Biologics Safety Testing (BST) softness Cost structure and commercial investment
Revenue
$69.03M
▲ 3.2% YoY
Diluted EPS
$-0.68
Gross margin
46.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Maravai Lifesciences Holdings, Inc. (MRVI) Q2 2024 Earnings Call Transcript
Positive tone Flanders facility ramp-up Margin and pricing dynamics New product introductions (NPI)
Revenue
$69.42M
▲ 0.7% YoY
Diluted EPS
$-0.07
Gross margin
44.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Maravai Lifesciences Holdings, Inc. (MRVI) Q1 2024 Earnings Call Transcript
Positive tone Nucleic Acid Production product innovation Return to growth strategy and commercial team Q1 financial results and cash position
Revenue
$64.18M
▼ 18.8% YoY
Diluted EPS
$-0.09
Gross margin
40.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Maravai Lifesciences Holdings, Inc. (MRVI) Q4 2023 Earnings Call Transcript
Positive tone CleanCap pipeline expansion Nucleic Acid Production segment Biologics Safety Testing segment
Revenue
$74.14M*
▼ 63.8% YoY
Gross margin
52.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Maravai Lifesciences Holdings, Inc. (MRVI) Q3 2023 Earnings Call Transcript
Revenue
$66.86M
▼ 65% YoY
Diluted EPS
$-0.05
▼ 114.7% YoY
Gross margin
45.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Maravai Lifesciences Holdings, Inc. (MRVI) Q2 2023 Earnings Call Transcript
Revenue
$68.91M
▼ 71.6% YoY
Diluted EPS
$-0.05
▼ 109.4% YoY
Gross margin
37.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Maravai Lifesciences Holdings, Inc. (MRVI) Q1 2023 Earnings Call Transcript
Revenue
$79.03M
▼ 67.7% YoY
Diluted EPS
$0.00
▼ 100% YoY
Gross margin
57.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-22
Maravai Lifesciences Holdings, Inc. (MRVI) Q4 2022 Earnings Call Transcript
Revenue
$204.71M*
▼ 10.4% YoY
Gross margin
74.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Maravai Lifesciences Holdings, Inc. (MRVI) Q3 2022 Earnings Call Transcript
Revenue
$191.26M
▼ 6.6% YoY
Diluted EPS
$0.34
▼ 22.7% YoY
Gross margin
80.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Maravai Lifesciences Holdings, Inc. (MRVI) Q2 2022 Earnings Call Transcript
Revenue
$242.73M
▲ 11.5% YoY
Diluted EPS
$0.53
▲ 20.5% YoY
Gross margin
84.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Maravai Lifesciences Holdings, Inc. (MRVI) Q1 2022 Earnings Call Transcript
Revenue
$244.29M
▲ 64.8% YoY
Diluted EPS
$0.50
▲ 108.3% YoY
Gross margin
83.6%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-23
Maravai Lifesciences Holdings, Inc. (MRVI) Q4 2021 Earnings Call Transcript
Revenue
$228.44M*
▲ 132.3% YoY
Gross margin
82.9%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Maravai Lifesciences Holdings, Inc. (MRVI) Q3 2021 Earnings Call Transcript
Revenue
$204.81M
▲ 133.1% YoY
Diluted EPS
$0.44
▲ 266.7% YoY
Gross margin
84.3%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-10
Maravai Lifesciences Holdings, Inc. (MRVI) Q2 2021 Earnings Call Transcript
Revenue
$217.78M
▲ 364.3% YoY
Diluted EPS
$0.44
Gross margin
82.6%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Maravai Lifesciences Holdings, Inc. (MRVI) Q1 2021 Earnings Call Transcript
Revenue
$148.21M
▲ 190.7% YoY
Diluted EPS
$0.24
▲ 166.7% YoY
Gross margin
78.8%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-02
Maravai Lifesciences Holdings, Inc. (MRVI) Q4 2020 Earnings Call Transcript
Revenue
$98.35M*
Gross margin
76.2%
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–27 of 27 webcasts
Key facts CIK 1823239 CUSIP 56600D107 13F (30d) 217 filings 198 filers Visit website Investor relations